US FDA finalizes SOP on communicating immediate changes in medtech reg expectations
This article was originally published in Clinica
Executive Summary
The US FDA's Center for Devices and Radiological Health has finalized a new process for rapidly informing stakeholders of any changes in the center's regulatory expectations that could affect data submitted as part of a pre-market submission or an investigational device exemption.